

# Silence Therapeutics PLC

07:29 28 May 2019

## Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments

Silence Therapeutics PLC (LON:SLN) has been given access to part of a genetic database as it bids to find treatments for rare diseases and ailments.

Genomics England has whole sequencing data on 100,000 genomes.

A genome is an organism's complete set of DNA, including all of its genes. Each genome contains the information needed to build and maintain that organism.

It is the key to understanding how people differ genetically and therefore how they might respond to different medicines.

### Data mining exercise

In the case of Silence, an expert in silencing disease-associated genes, having access to the database will help in its drug development effort.

Under the terms of the deal with Genomics England, Silence will "data mine" a subset of the information to focus on rare diseases and cardio-metabolic illnesses.

It wants to find disease-modifying target genes best suited to its unique technology.

The exercise should also help with "patient stratification" (dividing them into groups and sub-groups) and recruitment as the company develops its RNAi product candidates.

"This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities," said Silence chief executive, Dr David Horn Solomon.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which

**Price:** 210

**Market Cap:** £164.49 m

### 1 Year Share Price Graph



October 2018    April 2019    October 2019

### Share Information

**Code:** SLN

**Listing:** AIM

52 week	High	Low
	256	40

**Sector:** Pharma & Biotech

**Website:** [www.silence-therapeutics.com](http://www.silence-therapeutics.com)

### Company Synopsis:

*Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

